Skip to main content
. Author manuscript; available in PMC: 2011 Mar 30.
Published in final edited form as: Oncogene. 2010 Jul 12;29(39):5370–5380. doi: 10.1038/onc.2010.269

Figure 5. SLIT2 down-regulation in prostate cancer.

Figure 5

(a) SLIT2 expression in multiple cancer microarray datasets available in Oncomine (www.oncomine.com). (b) QRT-PCR analysis of SLIT2 and EZH2 transcripts in a cohort of 8 benign prostate hyperplasia (Benign), 7 localized prostate cancer (PCA), and 7 metastatic prostate cancer (MET) tissues. Expression of target genes was normalized to the amount of the GAPDH housekeeping gene. SLIT2 markedly (p = 0.0004 by t-test) lower in metastatic prostate cancers. (c) Immunoblot of SLIT2 in a cohort of 3 benign prostate hyperplasia (Benign), 4 localized prostate cancer (PCA), and 7 metastatic prostate cancer (MET) tissues. (d) Negative correlation (r = −0.47) between the transcript levels of EZH2 and SLIT2 in a cohort of prostate cancer analyzed by RNA-Seq. Scatter plot of EZH2 and SLIT2 expression was shown from all profiled samples in our in-house RNA-Seq analysis of 8 benign, 15 localized and 20 metastatic prostate tumors. Expression values are in RPKM (the number of mappable sequencing reads per million per killobase of cDNA sequence) (e) SLIT2 expression (in RPKM) analyzed by RNA-Seq as in (d). SLIT2 is downregulated in metastatic prostate cancers (p<0.001 by t-test).